Synthetic peptides representing 14 regions of the bovine enterovirus structural proteins were used to raise antibodies in mice. The peptides were predicted using amino acid sequence alignments with the position of antigenic sites on other picornaviruses. Five of the anti-peptide antibodies reacted with the virus in an immunoprecipitation test. Furthermore, each of these anti-peptide antibodies neutralized virus infectivity; those directed against peptides of VP2 and VP3 neutralized to a greater extent than those directed against peptides of VP1. The positions of these epitopes in the viral structural proteins are discussed in relation to corresponding positions in other picornaviruses.
Bovine enterovirus (BEV), a picornavirus belonging to the genus Enterovirus, is endemic in cattle but causes no clinically evident disease. Each virus particle is composed of one molecule of positive-stranded RNA encapsulated within 60 copies of each of the structural proteins VP1, VP2, VP3 and VP4 (Hoey & Martin, 1974) . Recent publications on the three-dimensional structures of other picornaviruses, human rhinovirus type 14 (HRV-14) (Rossmann et al., 1985) , poliovirus (Hogle et al., 1985) , Mengovirus (Luo et al., 1987) and foot-and-mouth disease virus (FMDV) (Acharya et al., 1989) have provided information on the location and orientation of the structural proteins within the capsid. In addition, the major neutralizing immunogenic epitopes on the viral surface in each of these viruses have been mapped using monoclonal antibody escape mutants for HRV-14 (Sherry & Rueckert, 1985; Sherry et al., 1986) , poliovirus Evans et al., 1983) and Mengovirus (Boege et al., 1989) and by using antibodies to synthetic peptides for FMDV (Bittle et al., 1982) .
By alignment of the amino acid sequences for BEV structural proteins (Earle et al., 1988) with those of other picornaviruses (Palmenberg, 1989) and by taking into consideration the available three-dimensional structures, potential immunogenic sites were selected. These were chosen on the basis of sequence variability and probability of appearance on the viral surface. A highly conserved region (peptide 4) was selected as a control. Peptides were synthesized by the Houghten (1985) adaptation of the Merrifield (1963) method and coupled in phosphate-buffered saline (PBS; 2 mg/ml) with 5% (w/v) glutaraldehyde to keyhole limpet haemocyanin (2 mg/ml). Ten to 15 ~tg of the conjugate was mixed with Freund's complete adjuvant and inoculated into BALB/c mice via the intraperitoneal route. Mice were boosted on day 28 using a similar quantity of conjugate in Freund's incomplete adjuvant and bled on day 35 after the first injection. Sera were tested by ELISA for anti-peptide activity. A direct ELISA was carried out with 100 ng per well of peptide which had been dried onto the plate from a solution of 0-2% (w/v) NaHCO 3, 0.2% (w/v) Na2CO 3 in water, and fixed for 5 min in methanol. Serial twofold dilutions of test antisera in PBS were added (100 ~1 per well). Peroxidase-conjugated anti-mouse IgG was added at 1 : 3000 in PBS. The substrate consisted of 1 M-sodium acetate-citric acid pH 6.0, containing 50 ~tg/ml of tetramethyl-benzidine, 0.5% (v/v) in DMSO, and 0-03% (v/v) H202. Reactions were stopped with 0.5 M-H2SO4. The endpoint was taken as the reciprocal dilution required to produce 50% of the maximum absorbance plateau of the control. All peptides, with the exception of peptide 8, elicited a response indicating that the peptides had been presented in such a manner as to induce a primary immune response (Table 1) . Preimmune serum did not react with any of the peptides.
Anti-peptide sera were also tested for the recognition of intact virus particles by radioimmunoprecipitation using the method of Bittle et al. (1982) . In this test antipeptide sera 5, 9, 10, 12 and 13 precipitated the virus particle (data not shown). These antisera were then tested for their ability to neutralize virus infectivity. 0000-9191 © 1990 SGM 
Poliovirus site 3b
Viruses were used at a dilution containing 200 p.f.u, and antisera were added in serial twofold dilutions from 1 : 10 to 1:320. Virus-antibody reactions were incubated at 37 °C for 1 h and applied to a monolayer of BHK ceils. Viruses were allowed to adsorb for 30 min at 37 °C after which the inoculum was removed and the cells were overlaid with agar (0.75~ w/v) containing 100 gg/ml of DEAE-dextran and Eagle's BHK medium. After 2 days at 37°C cells were fixed and stained in 1~ (v/v) formaldehyde, 0.02~o (w/v) crystal violet, 5~ (v/v) methanol in water. A 50~ reduction in plaque number was interpreted as the endpoint. All of the five antisera neutralized the virus but the peptides corresponding to sequences of VP2 and VP3 elicited higher levels of activity. Antisera to peptides 5, 9 and 13 at 10-fold dilution neutralized virus infectivity entirely. The corresponding positions of these sequences in the proteins of other picornaviruses are summarized in Table 2 .
Polypeptide 5 does not align to any other known picornavirus epitope and probably plays a minor role in the neutralization of BEV. However, by sequence alignment this region may correspond to a possible hepatitis A virus epitope (D. V. Sangar, personal communication).
Peptide 9 aligns with the FMDV epitope, 141 to 160, on VP1 and with poliovirus site 2a (serotype 1). Interestingly, peptides 7 and 8, from the N and C termini of peptide 9, respectively, gave different results. Peptide 7 gave the highest anti-peptide response but the antisera did not recognize intact virus particles by immunoprecipitation, whereas peptide 8 gave no measurable response. The lack of reaction of peptide 7 antisera with the virus may be because the conjugated peptide has a different conformation than on the virus particle. Peptide 10, located five residues from the C-terminal side of peptide 9, extends beyond the region of BEV VP1, which aligns with the 141 to 160 FMDV loop and the poliovirus loop, perhaps implying that the BEV loop is larger than in these viruses. Peptides from the other regions of poliovirus VP 1 have been reported not to elicit neutralizing antibody but to prime the immune system of rabbits for a subsequent injection of homologous virus (Emini et al., 1983) .
Peptide 12 aligns to poliovirus site 2b (serotypes 1 and 3) and to HRV-14 site NIm-IIA. The corresponding peptide from HRV-2 VP2 was reported to elicit antiviral activity but the responses were variable (Francis et al., 1987) . When neutralization was observed it was of a much lower order than that observed with the BEV peptide. Peptide 13, also giving very high neutralization titres, is derived from a region of BEV which aligns with only part of poliovirus site 3b (Minor et aL, 1986) . The complete site in this virus is highly dependent on conformation with contributions from other amino acids from VP3, and from VP1. Our data suggest that this site in BEV is more linear, although at present we cannot rule out the contribution of other amino acids to this major antigenic site. Peptides 12 and 13 also correspond to a single composite epitope on VP2 and VP3 of Mengovirus (Boege et al., 1989) . The major BEV neutralizing epitopes detected by this method align with those from FMDV, poliovirus, Mengovirus and HRV, emphasizing strong structural and antigenic similarities between the viruses. The strongest neutralization of BEV was shown by peptides derived from sites in VP2 and VP3. This result is comparable to those for HRV-2 and poliovirus type 1 but contrasts with the FMDV results.
Peptide 1 of BEV, corresponding to residues 89 to 100 of poliovirus VP1, failed to elicit antiviral activity. This site is immunodominant in poliovirus serotypes 2 and 3 (Minor et al., 1986 ) but may not be involved in the neutralization of BEV. However, it has been reported that the poliovirus peptide fails to elicit antiviral activity in mice or guinea-pigs, the activity being observed only in rabbits (Ferguson et al., 1985) , emphasizing the importance of host factors in responses to antigens.
The immunogenicity of the BEV peptides was much greater than that of HRV-2 (Francis et al., 1987) and of a similar order to that of the FMDV peptide (141 to 160) (Bittle et al., 1982) . This may be due to the method of presentation of the antigen or may reflect a similarity in conformation of the epitope on the virus particle. Irrespective of the reasons for the high responses compared with those obtained with the rhinovirus peptides, the results show clearly that continuous epitopes of BEV, like those from FMDV, are able to elicit high levels of neutralizing antibody. The antipeptide antibodies tested for neutralization in this study were those demonstrated to immunoprecipitate the complete virus particle. This does not preclude the possibility of the other anti-peptide antisera having neutralizing activity.
The use of synthetic peptide antisera allows the mapping of certain continuous immunoreactive sites on viruses. We are currently undertaking work using anti-BEV monoclonal antibodies to identify conformational epitopes.
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